Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
Business Wire•04/11/2026•09:00 ET
0
Key Highlights
- ➤Divesiran SANRECO Phase 2 data accepted for oral presentation at ASH 2026
- ➤ASH presentation scheduled December 14, 2026, at 3:30 PM CT
- ➤Divesiran is a first-in-class siRNA silencing TMPRSS6 in polycythemia vera
Expert Statements
Marina Kremyanskaya, MD PhD, Icahn School of Medicine at Mount Sinai
“Sanreco phase 2 randomized, double-blind trial of divesiran in patients with polycythemia vera”
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that data from its SANRECO Phase 2 study of divesiran, a first-in-class siRNA silencing TMPRSS6, in polycythemia vera (PV) was accepted for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting being held December 12-15, 2026 in New Orleans, LA.
Get started
Create a free account to read the full story.